Search results for "Neoplastic"

showing 10 items of 2901 documents

Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy

2006

The Cancer Imaging Program of the National Cancer Institute convened a workshop to assess the current status of hypoxia imaging, to assess what is known about the biology of hypoxia as it relates to cancer and cancer therapy, and to define clinical scenarios in which in vivo hypoxia imaging could prove valuable.Hypoxia, or low oxygenation, has emerged as an important factor in tumor biology and response to cancer treatment. It has been correlated with angiogenesis, tumor aggressiveness, local recurrence, and metastasis, and it appears to be a prognostic factor for several cancers, including those of the cervix, head and neck, prostate, pancreas, and brain. The relationship between tumor oxy…

Diagnostic ImagingOncologymedicine.medical_specialtyCancer therapyBiologyAntigens NeoplasmNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansRadiology Nuclear Medicine and imagingMedical physicsCarbonic Anhydrase IXHypoxiaCarbonic AnhydrasesCancer Imaging ProgramRadiological and Ultrasound TechnologyTumor biologyReproducibility of ResultsHypoxia (medical)PrognosisUnited StatesCancer treatmentIsoenzymesOxygenRadiographyNational Institutes of Health (U.S.)Hypoxia-Inducible Factor 1medicine.symptomInternational Journal of Radiation Biology
researchProduct

Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy

1993

Forty patients with chemotherapy-related diarrhea were randomized to receive (i) octreotide 0.5 mg three times per day s.c. or (ii) loperamide 4 mg three times per day p.o. until complete remission of diarrhea was achieved. In the octreotide group 80% of patients showed complete resolution of loose bowel movements within 4 days of therapy, while in the loperamide group this goal was obtained in only 30% of cases (p < 0.001). If after 4 days no benefit was seen, patients were considered to have failed antidiarrheal therapy. Failure was recorded in only one case (5%) treated with s.c. octreotide and in five patients (25%) who received loperamide. The mean duration of antidiarrheal therapy nec…

DiarrheaMaleLoperamidemedicine.medical_specialtyAbdominal painCancer Researchmedicine.medical_treatmentInjections SubcutaneousOctreotideAdministration OralOctreotideGastroenterologyLoperamidelaw.inventionRandomized controlled triallawChemotherapy-related diarrheaInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansPharmacology (medical)PharmacologyChemotherapybusiness.industryMiddle AgedClinical trialDiarrheaEndocrinologyOncologyChemotherapy-related diarrhea; Loperamide; Octreotide; Cancer Research; Oncology; PharmacologyDefecationFemalemedicine.symptombusinessmedicine.drug
researchProduct

Mid-region parathyroid hormone-related protein (PTHrP) and gene expression of MDA-MB231 breast cancer cells.

2007

Abstract We have previously shown that PTHrP(38–94) amide restrains growth and invasion in vitro, causes striking toxicity and accelerates death of some breast cancer cell lines, the most responsive being MDA-MB231, for which tumorigenesis was also attenuated in vivo. We have also demonstrated that mid-region PTHrP gains access to the nuclear compartment of these cells and displays DNA-binding properties in vitro by recognizing targets in both cellular chromatin and isolated oligonucleotides. Here, we examined whether PTHrP(38–94) amide was able to modulate gene expression of MDA-MB231 cells, employing a combination of conventional, differential display and semi-quantitative multiplex PCR t…

Differential displayParathyroid hormone-related proteinChemistryClinical BiochemistryMolecular Sequence DataParathyroid Hormone-Related ProteinBreast Neoplasmsmedicine.disease_causeBiochemistryIn vitroChromatinGene Expression Regulation NeoplasticCell Line TumorGene expressionmedicineCancer researchCytotoxic T cellHumansCarcinogenesisMolecular BiologyReprogrammingBiomarkersChromosomes Human Pair 8Biological chemistry
researchProduct

Cytotoxicity of cardiotonic steroids in sensitive and multidrug-resistant leukemia cells and the link with Na(+)/K(+)-ATPase.

2015

Cardiotonic steroids have long been in clinical use for treatment of heart failure and are now emerging as promising agents in various diseases, especially cancer. Their main target is Na(+)/K(+)-ATPase, a membrane protein involved in cellular ion homeostasis. Na(+)/K(+)-ATPase has been implicated in cancer biology by affecting several cellular events and signaling pathways in both sensitive and drug-resistant cancer cells. Hence, we investigated the cytotoxic activities of 66 cardiotonic steroids and cardiotonic steroid derivatives in sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 leukemia cells. Data were then subjected to quantitative structure-activity relationship analysis (QSA…

DigoxinCell SurvivalEndocrinology Diabetes and MetabolismClinical BiochemistryPrimary Cell CultureGene ExpressionQuantitative Structure-Activity RelationshipAntineoplastic AgentsBiologyPharmacologyBiochemistryCardiac GlycosidesEndocrinologyCellular ion homeostasisCell Line TumorCytotoxic T cellHumansNa+/K+-ATPaseCytotoxicityMolecular BiologyCell BiologyMolecular biologyDrug Resistance MultipleBlotBufanolidesMolecular Docking SimulationVerapamilCell cultureDoxorubicinDrug Resistance NeoplasmCancer cellLeukocytes MononuclearMolecular MedicineSignal transductionSodium-Potassium-Exchanging ATPaseSignal TransductionThe Journal of steroid biochemistry and molecular biology
researchProduct

Induction of Human P-Glycoprotein in Caco-2 cells: Development of a Highly Sensitive Assay System for P-Glycoprotein-Mediated Drug Transport

2006

The aim of this work is to develop a highly sensitive assay system for P-gp-mediated transport by using two methods, induction of P-gp and short-term culture of Caco-2 cells. To induce P-gp in Caco-2 cells, cells were cultured in vinblastine-containing medium. The mRNA level of P-gp was approximately 7-fold higher in Caco-2 cells cultured with vinblastine (P-gp-induced Caco-2 cells) than in control cells. Western blot analysis showed a significant increase in P-gp expression. After cell differentiation, the mRNA level of P-gp was downregulated, however, P-gp-induced Caco-2 cells still possessed a 5.6-fold higher mRNA level of P-gp compared to control cells. Polarized transport of substrate …

DigoxinCellular differentiationBlotting WesternGene ExpressionPharmaceutical ScienceCell Growth ProcessesVinblastinePeptide Transporter 1Cell LineCytochrome P-450 Enzyme SystemWestern blotmedicineAnimalsCytochrome P-450 CYP3AHumansPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1RNA MessengerP-glycoproteinPharmacologySymportersbiologymedicine.diagnostic_testMicrofilament ProteinsMembrane Transport ProteinsBiological TransportCell DifferentiationAntineoplastic Agents PhytogenicQuinidineMolecular biologyMultidrug Resistance-Associated Protein 2In vitroVinblastineBlotPharmaceutical PreparationsVerapamilCaco-2Cell culturebiology.proteinCaco-2 CellsMultidrug Resistance-Associated Proteinsmedicine.drugDrug Metabolism and Pharmacokinetics
researchProduct

Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma

2005

Renal cell carcinoma (RCC) representing the most common neoplasia of the kidney in Western countries is a histologic diverse disease with an often unpredictable course. The prognosis of RCC is worsened with the onset of metastasis, and the therapies currently available are of limited success for the treatment of metastatic RCC. Although gene expression analyses and other methods are promising tools clarifying and standardizing the pathological classification of RCC, novel innovative molecular markers for the diagnosis, prognosis, and for the monitoring of this disease during therapy as well as potential therapeutic targets are urgently needed. Using proteome-based strategies, a number of RC…

DiseaseBiologyFatty Acid-Binding ProteinsKidneyurologic and male genital diseasesmedicine.disease_causeBiochemistryMetastasisReference ValuesRenal cell carcinomaCell Line TumorBiomarkers TumormedicineCarcinomaHumansElectrophoresis Gel Two-DimensionalUrotheliumCarcinoma Renal CellneoplasmsMolecular BiologyDNA PrimersKidneyReverse Transcriptase Polymerase Chain ReactionPrognosismedicine.diseaseImmunohistochemistryKidney Neoplasmsfemale genital diseases and pregnancy complicationsGene Expression Regulation Neoplasticmedicine.anatomical_structureImmunologyDisease ProgressionCancer researchUrotheliumCarrier ProteinsCarcinogenesisKidney diseasePROTEOMICS
researchProduct

Polyoxygenated Cyclohexenes and Other Constituents of Cleistochlamys kirkii Leaves.

2016

Thirteen new metabolites, including the polyoxygenated cyclohexene derivatives cleistodiendiol (1), cleistodienol B (3), cleistenechlorohydrins A (4) and B (5), cleistenediols A-F (6-11), cleistenonal (12), and the butenolide cleistanolate (13), 2,5-dihydroxybenzyl benzoate (cleistophenolide, 14), and eight known compounds (2, 15-21) were isolated from a MeOH extract of the leaves of Cleistochlamys kirkii. The purified metabolites were identified by NMR spectroscopic and mass spectrometric analyses, whereas the absolute configurations of compounds 1, 17, and 19 were established by single-crystal X-ray diffraction. The configuration of the exocyclic double bond of compound 2 was revised base…

Double bondStereochemistryCyclohexenesPlasmodium falciparumCyclohexenePharmaceutical ScienceBreast Neoplasms01 natural sciencesAnalytical Chemistrychemistry.chemical_compoundAntimalarialsInhibitory Concentration 50X-Ray DiffractionDrug DiscoveryCyclohexenesHumansta116metabolitesCleistochlamys kirkiiButenolidePharmacologychemistry.chemical_classificationMolecular Structure010405 organic chemistryOrganic Chemistryspectrometric analysesMass spectrometricAntineoplastic Agents Phytogenic3. Good health0104 chemical sciencesPlant Leaves010404 medicinal & biomolecular chemistryCleistophenolideHEK293 CellsComplementary and alternative medicinechemistryMolecular MedicineJournal of natural products
researchProduct

Synthesis of N-acyl Derivatives of Aminocombretastatin A-4 and Study of their Interaction with Tubulin and Downregulation of c-Myc.

2021

11 p.-9 fig.-4 tab.

Down-RegulationAntineoplastic AgentsMicrotubule dynamicsStructure-Activity RelationshipDownregulation and upregulationMicrotubuleTubulinCell Line TumorDrug DiscoveryHumansMTT assayAminocombretastatin A-4Cell ProliferationbiologyChemistryCell growthIn vitroTubulin ModulatorsMolecular Docking SimulationTubulinc-MycBiochemistryCell cultureDocking (molecular)biology.proteinDrug Screening Assays AntitumorAnti-proliferative activityAnti-mitoticMedicinal chemistry (Shariqah (United Arab Emirates))
researchProduct

Unraveling the interaction between doxorubicin and DNA origami nanostructures for customizable chemotherapeutic drug release

2021

We thank Dr H. Häkkänen for technical assistance and S. Julin for the 24HB DNA origami design. We acknowledge the provision of facilities and technical support by Aalto University Bioeconomy Facilities and OtaNano – Nanomicroscopy Center (Aalto-NMC). The research was carried out under the Academy of Finland Centres of Excellence Programme (2014–2019). Academy of Finland [308578 to M.A.K.]; Deutsche Forschungsgemeinschaft [Emmy Noether Programme to A.H.-J., SFB1032 (Project A06) to T.L.]; Emil Aaltonen Foundation [to H.I. and V.L.]; Jane and Aatos Erkko Foundation [to J.A.I. and V.L.]; Sigrid Jusélius Foundation [to V.L.]; Vilho, Yrjö and Kalle Väisälä Foundation of the Finnish Academy of Sc…

Drug CarriersAntibiotics AntineoplasticAcademicSubjects/SCI00010organic chemicalstechnology industry and agricultureMagnesium Chloridelääkeaineetmacromolecular substancesDNABuffersnanolääketiedeNanostructurescarbohydrates (lipids)Drug LiberationnanorakenteetChemical Biology and Nucleic Acid ChemistryDoxorubicinpolycyclic compoundsDeoxyribonuclease INucleic Acids Research
researchProduct

Loading, release and stability of epirubicin-loaded drug-eluting beads.

2015

Purpose The aim of this study was to determine the loading efficiency, physico-chemical stability and release of epirubicin-loaded DC Bead™ (Biocompatibles UK Ltd, a BTG International group company) (bead size 70–150 µm (=DC Bead M1™) and 100–300 µm) after loading with epirubicin solution (2 mg/ml) or reconstituted powder formulation (25 mg/ml) and controlled storage. Methods DC Bead™ were loaded with 76 mg epirubicin solution (Epimedac™, Medac GmbH) or 75 mg epirubicin powder formulation (Farmorubicin™, Pharmacia Pfizer GmbH) per 2 ml of beads. Drug loading efficiency and stability were determined by measuring the epirubicin concentration in the excess solution after predetermined interval…

Drug CompoundingDrug StorageBead030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineDrug StabilitymedicinePharmacology (medical)Particle SizeChromatography High Pressure LiquidEpirubicinDrug CarriersChromatographyAntibiotics AntineoplasticDrug eluting beadsElutionbusiness.industrySyringesMicrospheresOncology030220 oncology & carcinogenesisvisual_artDrug releasevisual_art.visual_art_mediumPowdersbusinessEpirubicinmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct